KFA Private Wealth Group LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

KFA Private Wealth Group LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,428 shares of the medical research company’s stock after purchasing an additional 96 shares during the quarter. KFA Private Wealth Group LLC’s holdings in Amgen were worth $411,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Briaud Financial Planning Inc purchased a new stake in shares of Amgen during the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. purchased a new stake in Amgen in the 4th quarter worth approximately $29,000. OFI Invest Asset Management purchased a new stake in Amgen in the 3rd quarter worth approximately $26,000. Planned Solutions Inc. purchased a new stake in Amgen in the 4th quarter worth approximately $30,000. Finally, Providence Capital Advisors LLC purchased a new stake in Amgen in the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $0.60 during midday trading on Friday, reaching $269.98. 2,436,947 shares of the stock traded hands, compared to its average volume of 2,822,655. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a market capitalization of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.54 and a beta of 0.58. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company’s 50 day moving average is $275.10 and its 200 day moving average is $281.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s revenue was up 19.8% on a year-over-year basis. During the same period last year, the company earned $4.09 earnings per share. On average, equities research analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Raymond James assumed coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. TD Cowen dropped their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.